Citius Oncology, Inc. (CTOR)
NASDAQ:CTOR
Want to see CTOR full AI Analyst Report?
Top Page
Citius Oncology
(NASDAQ:CTOR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.85
▼(-20.84% Downside)
Action:ReiteratedDate:04/30/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn implying funding risk). Technicals are only mildly positive and remain below key longer-term averages. Corporate events provide some upside from LYMPHIR progress but are tempered by Nasdaq non-compliance risk, while valuation support is limited due to negative earnings and no dividend.
Positive Factors
Early Commercial Traction
Sustained early adoption across academic and community centers (sequential orders, repeat purchases, broad formulary progress) indicates LYMPHIR is gaining clinical and payer acceptance. For a pre-revenue oncology firm, durable institutional uptake improves commercialization probability, supports scaling, and de-risks future revenue generation.
Negative Factors
Pre-Revenue with Growing Losses
The company remains pre-revenue while operating and net losses have materially widened, depleting equity and increasing funding reliance. Over the medium term this structural operating deficit raises dilution risk, constrains reinvestment capacity, and magnifies execution risk absent sustained revenue ramp or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Early Commercial Traction
Sustained early adoption across academic and community centers (sequential orders, repeat purchases, broad formulary progress) indicates LYMPHIR is gaining clinical and payer acceptance. For a pre-revenue oncology firm, durable institutional uptake improves commercialization probability, supports scaling, and de-risks future revenue generation.
Read all positive factors
Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.92M
Dividend YieldN/A
Average Volume (3M)203.68K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,275,210
10 Day Avg. Volume144,494
30 Day Avg. Volume203,680
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue18.36
Enterprise Value/Gross Profit22.96
Enterprise Value/Ebitda-3.33
Forecast
1Y Price Target
$6.00Price Target Upside460.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$38.87M
Citius Oncology Business Overview & Revenue Model
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The compa...
How the Company Makes Money
As of publicly available information, CTOR’s revenue-generating commercial operations are null. The company is primarily a development-stage oncology company, so its funding and cash inflows are generally expected to come from non-operating source...
Citius Oncology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -21.74M | -23.49M | -20.57M | -12.12M | 0.00 |
| Net Income | -23.64M | -24.76M | -21.15M | -12.70M | -10.87M |
Balance Sheet | |||||
| Total Assets | 109.97M | 100.94M | 84.37M | 47.73M | 42.69M |
| Cash, Cash Equivalents and Short-Term Investments | 7.30M | 3.92M | 112.00 | 0.00 | 0.00 |
| Total Debt | 3.80M | 3.80M | 3.80M | 0.00 | 0.00 |
| Total Liabilities | 51.56M | 56.08M | 38.23M | 22.20M | 6.42M |
| Stockholders Equity | 58.41M | 44.87M | 46.14M | 25.54M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -12.89M | -5.49M | 126.35K | -601.30K | -47.97K |
| Operating Cash Flow | -12.89M | -5.49M | 126.35K | -601.30K | -47.97K |
| Investing Cash Flow | -10.19M | -5.75M | -5.00M | -1.32M | -67.32M |
| Financing Cash Flow | 30.41M | 15.17M | 4.87M | 1.66M | 67.66M |
Citius Oncology Technical Analysis
Neutral
1.07
Price Trends
0.89
Negative
1.02
Negative
1.48
Negative
Market Momentum
-0.01
Negative
61.75
Neutral
81.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Neutral. The current price of 1.07 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.89, and below the 200-day MA of 1.48, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 61.75 is Neutral, neither overbought nor oversold. The STOCH value of 81.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTOR.
Citius Oncology Risk Analysis
Citius Oncology disclosed 52 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $28.70B | 19.96 | 7.28% | ― | 2.88% | -21.29% | |
59 Neutral | $3.50B | 9.95 | 25.50% | 4.80% | -2.92% | -78.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.41B | 14.03 | 7.56% | 1.56% | 9.11% | 170.10% | |
47 Neutral | $75.92M | -3.95 | -55.19% | ― | ― | ― | |
43 Neutral | $34.26M | -0.22 | 435.85% | ― | ― | ― |
* Healthcare Sector Average
CTOR
Citius Oncology
0.88
-0.01
-1.24%
BIIB
Biogen
189.28
68.35
56.52%
GRFS
Grifols SA
8.24
1.31
18.90%
SRXH
SRx Health Solutions
0.11
-1.12
-90.81%
SCLX
Scilex Holding Company
10.52
5.42
106.27%
OGN
Organon
13.25
3.89
41.57%
Citius Oncology Corporate Events
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Begins First European Expansion of LYMPHIR
Positive
Apr 29, 2026
On April 29, 2026, Citius Oncology announced it had shipped the first international order of LYMPHIR to Europe via a regional distribution partner, expanding access to the CTCL therapy outside the U.S. under Named Patient Programs in select market...
Delistings and Listing ChangesRegulatory Filings and Compliance
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
Negative
Apr 28, 2026
On April 22, 2026, Citius Oncology disclosed that it received a notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering non-compliance with Nasdaq’s listing requireme...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Citius Oncology highlights early LYMPHIR commercial traction, expansion
Positive
Apr 1, 2026
On March 31, 2026, Citius Oncology reported early commercial traction for LYMPHIR (denileukin diftitox-cxdl) in the U.S. following its December 2025 launch for relapsed or refractory cutaneous T-cell lymphoma. The company highlighted sequential or...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
Positive
Mar 10, 2026
On March 10, 2026, Citius Oncology reported positive topline data from a completed investigator-initiated Phase 1 trial led by University of Pittsburgh researchers evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or ...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
Positive
Mar 4, 2026
On March 4, 2026, Citius Oncology reported positive topline safety and efficacy data from an investigator-initiated Phase 1 trial of LYMPHIR administered before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse lar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.